This study is to evaluate the safety and preliminary efficacy of adding the PI3K-gamma inhibitor, eganelisib, to a standard of care treatment option with combi…

Leukemia, MyeloidLeukemiaAcute Myeloid Leukemia+1 more

~Estimated

~$10 – $7,500

Jacqueline Garcia, MDNCT07439211

Phase 1

A Phase 1/2 Study of the Menin Inhibitor Revumenib With the CELMod Mezigdomide in Relapsed/Refractory KMT2A-rearanged, NPM1-mutant, and NUP98-rearranged Acute Leukemias

The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-…

LeukemiaAcute LeukemiaRelapse Leukemia+5 more

~Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07356154

Phase 1

A Phase 1/2, Open Label, Study of Roginolisib (IOA-244), an Orally Bioavailable, Selective PI3Kδ Inhibitor in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) in Combination With Venetoclax and Rituximab

This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants wi…

LeukemiaRelapsed LeukemiaChronic Lymphocytic Leukemia+2 more

~Estimated

~$10 – $7,500

Jennifer R. Brown, MD, PhDNCT06644183